Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
COVID-19, An early investigation from exposure to treatment outcomes in Tehran, Iran.
Ashraf MA, Shokouhi N, Shirali E, Davari-Tanha F, Shirani K, Memar O, Kamalipour A, Azarnoush A, Mabadi A, Ossareh A, Sanginabadi M, Azad TM, Aghaghazvini L, Ghaderkhani S, Poordast T, Pourdast A, Nazemi P. Ashraf MA, et al. Among authors: aghaghazvini l. J Res Med Sci. 2021 Nov 29;26:114. doi: 10.4103/jrms.JRMS_1088_20. eCollection 2021. J Res Med Sci. 2021. PMID: 35126577 Free PMC article.
Predictive value of initial CT scan for various adverse outcomes in patients with COVID-19 pneumonia.
Khosravi B, Aghaghazvini L, Sorouri M, Naybandi Atashi S, Abdollahi M, Mojtabavi H, Khodabakhshi M, Motamedi F, Azizi F, Rajabi Z, Kasaeian A, Sima AR, Davarpanah AH, Radmard AR. Khosravi B, et al. Among authors: aghaghazvini l. Heart Lung. 2021 Jan-Feb;50(1):13-20. doi: 10.1016/j.hrtlng.2020.10.005. Epub 2020 Oct 14. Heart Lung. 2021. PMID: 33097297 Free PMC article.
Effect of nanocurcumin supplementation on the severity of symptoms and length of hospital stay in patients with COVID-19: A randomized double-blind placebo-controlled trial.
Honarkar Shafie E, Taheri F, Alijani N, Okhovvat AR, Goudarzi R, Borumandnia N, Aghaghazvini L, Rezayat SM, Jamalimoghadamsiahkali S, Hosseinzadeh-Attar MJ. Honarkar Shafie E, et al. Among authors: aghaghazvini l. Phytother Res. 2022 Feb;36(2):1013-1022. doi: 10.1002/ptr.7374. Epub 2022 Jan 12. Phytother Res. 2022. PMID: 35023260 Clinical Trial.
Cell therapy in patients with COVID-19 using Wharton's jelly mesenchymal stem cells: a phase 1 clinical trial.
Saleh M, Vaezi AA, Aliannejad R, Sohrabpour AA, Kiaei SZF, Shadnoush M, Siavashi V, Aghaghazvini L, Khoundabi B, Abdoli S, Chahardouli B, Seyhoun I, Alijani N, Verdi J. Saleh M, et al. Among authors: aghaghazvini l. Stem Cell Res Ther. 2021 Jul 16;12(1):410. doi: 10.1186/s13287-021-02483-7. Stem Cell Res Ther. 2021. PMID: 34271988 Free PMC article. Clinical Trial.
Cardiopulmonary predictors of mortality in patients with COVID-19: What are the findings?
Kavosi H, Nayebi Rad S, Atef Yekta R, Tamartash Z, Dini M, Javadi Nejad Z, Aghaghazvini L, Javinani A, Mohammadzadegan AM, Fotook Kiaei SZ. Kavosi H, et al. Among authors: aghaghazvini l. Arch Cardiovasc Dis. 2022 Jun-Jul;115(6-7):388-396. doi: 10.1016/j.acvd.2022.04.008. Epub 2022 Jun 8. Arch Cardiovasc Dis. 2022. PMID: 35752584 Free PMC article.
42 results